Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Genuit Group Plc LSE:GEN London Ordinary Share GB00BKRC5K31 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.00 -0.78% 379.50 378.00 378.50 383.50 370.00 375.50 507,141 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Industrial Engineering 594.3 62.9 16.7 22.7 942

Genmab A/S Capital Increase In Genmab As A Result Of Employee Warrant Exercise

17/08/2021 7:51pm

UK Regulatory (RNS & others)


Genuit (LSE:GEN)
Historical Stock Chart


From Jul 2021 to Jul 2022

Click Here for more Genuit Charts.
 
TIDMGEN 
 

Company Announcement

COPENHAGEN, Denmark; August 17, 2021 -- https://www.globenewswire.com/Tracker?data=hJ7P9F4JTsuzyTAH9UKDB2JATiXpZS-ZGV6yl92MFN_Z4Cg5zN7Zv2pcZxVJ8CvTK8HX01oGTI54Do2P1M9OTQ== Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,370 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

200 shares at DKK 220.40,

1,100 shares at DKK 466.20,

200 shares at DKK 623.50,

750 shares at DKK 636.50,

478 shares at DKK 815.50,

3,950 shares at DKK 939.50,

575 shares at DKK 962.00,

1,157 shares at DKK 1,032.00,

1,077 shares at DKK 1,136.00,

2,419 shares at DKK 1,145.00,

40 shares at DKK 1,233.00,

24 shares at DKK 1,424.00, and

400 shares at DKK 1,432.00

Proceeds to the company are approximately DKK 11.7 million. The increase corresponds to approximately 0.02% of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No. 1767 of November 27, 2020, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 65,681,084 which is made up of 65,681,084 shares of a nominal value of DKK 1 each, corresponding to 65,681,084 votes.

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com https://www.globenewswire.com/Tracker?data=hJ7P9F4JTsuzyTAH9UKDB5TKfd6zDC5lSLSsXNjAhUzo0QzuGN07xFkF9Q3GznhuSoAL9h1SA2DGxrmAiMyvCg== .

Contact:

Marisol Peron, Senior Vice President, Global Investor Relations & Communications

T: +1 609 524 0065; E: mmp@genmab.com https://www.globenewswire.com/Tracker?data=_QZlHvyIeukJ5ywKD-4SZdIwkYstoAYG-yfue9kT1hu5WVa-VRikNJ46i7wsaKiwNwszSnVYrgiJonbV0R1S0w==

For Investor Relations:

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com https://www.globenewswire.com/Tracker?data=Y2-pq-rTwOfuwLh2xrsER1ZciwdSBv7wkJLO1NrqCtD27fU_O_QTB2M6L0aRMuDwpFDZVDeUXTOlDdXHMOB3iA==

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on https://www.globenewswire.com/Tracker?data=bOV4yR4KyuZpchwll0N-pZshrcv0ZPOwhCmFFiivdi_QVrFnyY9a9yiwoPc9VraanbUZsOSOrY0rRov7MolhGQ== www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at https://www.globenewswire.com/Tracker?data=bOV4yR4KyuZpchwll0N-pSCrLDL3V3TiWIhCPJROw2W281Vl27LYS7TEIE-PYqyx7PsGoUD_CMD76zgLNWMZW3gAQ3MAhm9w74U97VzpsH4= www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in combination with the HexaBody logo(R) ; DuoHexaBody(R) and HexElect(R) .

Company Announcement no. 61

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

   -- 081721_CA61_Warrant Exercise 
      https://ml-eu.globenewswire.com/Resource/Download/7bfabfd0-f3fd-42ce-af57-3b07f50d2502 
 
 
 

(END) Dow Jones Newswires

August 17, 2021 14:51 ET (18:51 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Genuit Chart

1 Year Genuit Chart

1 Month Genuit Chart

1 Month Genuit Chart
ADVFN Advertorial
Your Recent History
LSE
GEN
Genuit
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220701 19:57:14